Asymptomatic or "silent" atrial fibrillation frequency in untreated patients and patients receiving azimilide

Circulation

Volumn 107, Issue 8, 2003, Pages 1141-1145

  Page, Richard L ^a,b,c,f   Tilsch, Thomas W ^b   Connolly, Stuart J ^d   Schnell, Daniel J ^b   Marcello, Stephen R ^b   Wilkinson, William E ^e   Pritchett, Edward L C ^e  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Division of Cardiology   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antiarrhythmia agents; Atrial flutter; Drugs; Fibrillation

Indexed keywords

AZIMILIDE; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINUS RHYTHM; STROKE; TREATMENT OUTCOME;

ADULT; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; KINETICS; MALE; MIDDLE AGED; PIPERAZINES; RECURRENCE;

EID: 0037418332     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000051455.44919.73     Document Type: Article

References (25)

1. Prystowsky EN, Benson DW, Fuster V, et al. AHA Medical/Scientific Statement Special Report: management of patients with atrial fibrillation: a statement for Healthcare Professionals from the subcommittee on Electrocardiography and Electrophysiology. American Heart Association. Circulation. 1996;93:1262-1277.
2. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1266.
3. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
4. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation. 1994;89:224-227.
5. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Intervent Cardiac Electrophysiol. 2000;4:369-382.
6. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham Study. Stroke. 1983;14:664-667.
7. Lin H-J, Wolf PM, Benjamin EJ, et al. Newly diagnosed atrial fibrillation and acute stroke: the Framingham Study. Stroke. 1995;26:1527-1530.
8. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation. 1989;80:1557-1570.
9. Atrial Fibrillation Investigation with Bidisomide (AFIB) Investigators. Treatment of atrial fibrillation and paroxysmal supraventricular tachycardia with bidisomide. Circulation. 1997;96:2625-2632.
10. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oval dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000102:2385-2390.
11. Pritchett ELC, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy dose response. J Am Coll Cardiol. 2000;36:794-802.
12. Connolly SJ, Schnell DJ, Page RL, et al. Dose response relation of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am J Cardiol. 2001;88:974-979.
13. Page RL, Connolly SJ, Wilkinson WE, et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and doseresponse. Am Heart J. 2002;143:643-649.
14. Collet D. Modeling Survival Data in Medical Research. London, UK: Chapman, Hall; 1994.
15. Kleinbaum DG, Kupper LL, Muller KE, Applied Regression Analysis, and Other Multivariable Methods. Boston, Mass: PWS-KENT Publishing Company; 1988:497-512.
16. Kerr C, Boone J, Connolly S, et al. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J. 1996;17(Suppl C):48-51.
17. DeFaye P, Dournaux F, Mouton E, et al. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. PACE. 1998;21(part II):250-255.
18. Wolk R, Kulakowski P, Karczmarewicz S, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone. Int J Cardiol. 1996;54:207-211.
19. Kühlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36:139-146.
20. Page RL. Beta-blockers for atrial fibrillation: must we consider asymptomatic arrhythmias? J Am Coll Cardiol. 2000;36:147-150.
21. Murgatroyd FD, Gibson SM, Xie B, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation. 1999;99:2765-2770.
22. Friedman PA, Dijkman B, Warman EN, et al. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation. 2001;104:1023-1028.
23. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 35:183-187.
24. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
25. Clair WK, Wilkinson WE, McCarthy EA, et al. The spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. Circulation. 1993;87:1114-1122.